Bioray Biotech Co., Ltd (TPEX:7561)
Taiwan · Delayed Price · Currency is TWD 27.00
+0.15 (0.56%)
Sep 18, 2025, 1:14 PM CST
Bioray Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| 230.06 | 201.71 | 191.83 | 190.6 | 148.02 | 156.3 | Upgrade | |
Revenue Growth (YoY) | 25.32% | 5.15% | 0.65% | 28.77% | -5.30% | -14.09% | Upgrade |
Cost of Revenue | 122.46 | 122.69 | 114.18 | 110.09 | 80.73 | 88.44 | Upgrade |
Gross Profit | 107.59 | 79.03 | 77.65 | 80.51 | 67.29 | 67.86 | Upgrade |
Selling, General & Admin | 43.24 | 47.66 | 52.73 | 48.48 | 53.55 | 53.36 | Upgrade |
Research & Development | 28.54 | 35.25 | 44.27 | 32.26 | 21.86 | 14.41 | Upgrade |
Operating Expenses | 72.08 | 83.34 | 96.98 | 80.82 | 75.4 | 68.08 | Upgrade |
Operating Income | 35.52 | -4.32 | -19.33 | -0.31 | -8.11 | -0.22 | Upgrade |
Interest Expense | -0.79 | -1.33 | -1.32 | -1.36 | -0.95 | -1.17 | Upgrade |
Interest & Investment Income | 1.36 | 1.27 | 0.65 | 0.19 | 0.05 | 0.14 | Upgrade |
Currency Exchange Gain (Loss) | 0.18 | 0.18 | -0.18 | -0.13 | -0.18 | -0.53 | Upgrade |
Other Non Operating Income (Expenses) | 1.41 | 5.02 | 7.09 | 2.12 | 3.02 | 3.19 | Upgrade |
EBT Excluding Unusual Items | 37.68 | 0.83 | -13.09 | 0.5 | -6.17 | 1.4 | Upgrade |
Impairment of Goodwill | - | - | -1.3 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.21 | Upgrade |
Gain (Loss) on Sale of Assets | -0.05 | -0.05 | 0.2 | 0.18 | - | -3.06 | Upgrade |
Other Unusual Items | 0.6 | 0.6 | - | - | - | - | Upgrade |
Pretax Income | 38.23 | 1.38 | -14.19 | 0.68 | -6.17 | -1.46 | Upgrade |
Income Tax Expense | 7.73 | 0.38 | -2.63 | 0.18 | 1.76 | -0.04 | Upgrade |
Earnings From Continuing Operations | 30.5 | 1 | -11.56 | 0.5 | -7.93 | -1.41 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 0.74 | 1.36 | Upgrade |
Net Income | 30.5 | 1 | -11.56 | 0.5 | -7.19 | -0.06 | Upgrade |
Net Income to Common | 30.5 | 1 | -11.56 | 0.5 | -7.19 | -0.06 | Upgrade |
Shares Outstanding (Basic) | 30 | 30 | 30 | 28 | 27 | 27 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 28 | 27 | 27 | Upgrade |
Shares Change (YoY) | -2.01% | -0.83% | 7.37% | 4.67% | 0.14% | -0.09% | Upgrade |
EPS (Basic) | 1.03 | 0.03 | -0.38 | 0.02 | -0.27 | -0.00 | Upgrade |
EPS (Diluted) | 1.03 | 0.03 | -0.38 | 0.02 | -0.27 | -0.00 | Upgrade |
Free Cash Flow | 31.26 | 13.43 | -10.78 | -57.16 | -6.15 | -49.32 | Upgrade |
Free Cash Flow Per Share | 1.06 | 0.45 | -0.36 | -2.04 | -0.23 | -1.84 | Upgrade |
Dividend Per Share | - | - | - | 0.200 | - | - | Upgrade |
Gross Margin | 46.77% | 39.18% | 40.48% | 42.24% | 45.46% | 43.42% | Upgrade |
Operating Margin | 15.44% | -2.14% | -10.08% | -0.16% | -5.48% | -0.14% | Upgrade |
Profit Margin | 13.26% | 0.50% | -6.03% | 0.26% | -4.86% | -0.04% | Upgrade |
Free Cash Flow Margin | 13.59% | 6.66% | -5.62% | -29.99% | -4.15% | -31.56% | Upgrade |
EBITDA | 50.86 | 12.05 | -1.66 | 15.79 | 5.32 | 9.36 | Upgrade |
EBITDA Margin | 22.11% | 5.97% | -0.86% | 8.29% | 3.59% | 5.99% | Upgrade |
D&A For EBITDA | 15.34 | 16.37 | 17.67 | 16.11 | 13.43 | 9.58 | Upgrade |
EBIT | 35.52 | -4.32 | -19.33 | -0.31 | -8.11 | -0.22 | Upgrade |
EBIT Margin | 15.44% | -2.14% | -10.08% | -0.16% | -5.48% | -0.14% | Upgrade |
Effective Tax Rate | 20.22% | 27.39% | - | 26.69% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.